{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:35:08Z","timestamp":1791668108117,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK072482"],"award-info":[{"award-number":["P30DK072482"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002548"],"award-info":[{"award-number":["UL1TR002548"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR003096"],"award-info":[{"award-number":["UL1TR003096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["2P30DK072482-12"],"award-info":[{"award-number":["2P30DK072482-12"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["UL1TR003096-01"],"award-info":[{"award-number":["UL1TR003096-01"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jcf.2021.08.007","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T02:36:45Z","timestamp":1631846205000},"page":"1026-1034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis"],"prefix":"10.1016","volume":"20","author":[{"given":"J. Stuart","family":"Elborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-9722","authenticated-orcid":false,"given":"Jennifer L.","family":"Taylor-Cousar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-1486","authenticated-orcid":false,"given":"Isabelle","family":"Fajac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1828-0058","authenticated-orcid":false,"given":"Alexander","family":"Horsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivagurunathan","family":"Sutharsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn D.","family":"Aaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cori L.","family":"Daines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Uluer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian G.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzina V.","family":"Lucidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Springman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Grosswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-0133","authenticated-orcid":false,"given":"Steven M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2021.08.007_bib0001","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2021.08.007_bib0002","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/thx.2007.082388","article-title":"Neutrophils in cystic fibrosis","volume":"64","author":"Downey","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2021.08.007_bib0003","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1164\/rccm.201606-1107CI","article-title":"Australian respiratory early surveillance team for Cystic F. Early lung disease in infants and preschool children with cystic fibrosis. What have we learned and what should we do about it?","volume":"195","author":"Ranganathan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2021.08.007_bib0004","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","article-title":"Inflammation in cystic fibrosis lung disease: pathogenesis and therapy","volume":"14","author":"Cantin","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.08.007_bib0005","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"Sly","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2021.08.007_bib0006","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199503303321303","article-title":"Effect of high-dose ibuprofen in patients with cystic fibrosis","volume":"332","author":"Konstan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2021.08.007_bib0007","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1513\/AnnalsATS.201706-486OC","article-title":"Association of high-dose ibuprofen use, lung function decline, and long-term survival in children with cystic fibrosis","volume":"15","author":"Konstan","year":"2018","journal-title":"Ann Am Thorac Soc."},{"key":"10.1016\/j.jcf.2021.08.007_bib0008","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jpeds.2007.04.009","article-title":"High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial","volume":"151","author":"Lands","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2021.08.007_bib0009","article-title":"Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis","volume":"4","author":"Lands","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2021.08.007_bib0010","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1124\/jpet.103.052449","article-title":"Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects","volume":"306","author":"Konstan","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jcf.2021.08.007_bib0011","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1164\/ajrccm\/141.1.186","article-title":"Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis","volume":"141","author":"Konstan","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jcf.2021.08.007_bib0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.smim.2017.07.002","article-title":"The role of the LTB4-BLT1 axis in chemotactic gradient sensing and directed leukocyte migration","volume":"33","author":"Subramanian","year":"2017","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jcf.2021.08.007_bib0013","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/adc.68.3.389","article-title":"Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis","volume":"68","author":"Greally","year":"1993","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jcf.2021.08.007_bib0014","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/ajrccm\/148.4_Pt_1.896","article-title":"Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis","volume":"148","author":"Konstan","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jcf.2021.08.007_bib0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MCP.0b013e32831311e8","article-title":"Ibuprofen therapy for cystic fibrosis lung disease: revisited","volume":"14","author":"Konstan","year":"2008","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2021.08.007_bib0016","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1378\/chest.115.4.1053","article-title":"The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes","volume":"115","author":"Oermann","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2021.08.007_bib0017","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2021.08.007_bib0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2021.08.007_bib0019","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2021.08.007_bib0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2021.08.007_bib0021","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/cts.12428","article-title":"Phase I studies of acebilustat: biomarker response and safety in patients with cystic fibrosis","volume":"10","author":"Elborn","year":"2017","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jcf.2021.08.007_bib0022","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cct.2018.07.014","article-title":"EMPIRE-CF: a phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - study design and patient demographics","volume":"72","author":"Elborn","year":"2018","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jcf.2021.08.007_bib0023","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2021.08.007_bib0024","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jcf.2010.05.004","article-title":"Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint","volume":"9","author":"Konstan","year":"2010","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.08.007_bib0025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jcf.2011.07.003","article-title":"Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint","volume":"10","author":"Vandevanter","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.08.007_bib0026","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/thx.2011.161117","article-title":"Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis","volume":"66","author":"de Boer","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2021.08.007_bib0027","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcf.2012.03.009","article-title":"Risk factors for rate of decline in FEV1 in adults with cystic fibrosis","volume":"11","author":"Konstan","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.08.007_bib0028","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1183\/09031936.00119714","article-title":"A contemporary survival analysis of individuals with cystic fibrosis: a cohort study","volume":"45","author":"Stephenson","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2021.08.007_bib0029","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jcf.2013.12.009","article-title":"A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis","volume":"13","author":"Konstan","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.08.007_bib0030","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccm.2007.02.002","article-title":"Inflammation and anti-inflammatory therapies for cystic fibrosis","volume":"28","author":"Chmiel","year":"2007","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jcf.2021.08.007_bib0031","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcf.2013.10.007","article-title":"BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs","volume":"13","author":"Doring","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.08.007_bib0032","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1164\/rccm.200609-1354OC","article-title":"Association between pulmonary function and sputum biomarkers in cystic fibrosis","volume":"175","author":"Mayer-Hamblett","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2021.08.007_bib0033","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jcf.2015.03.007","article-title":"Use of ibuprofen to assess inflammatory biomarkers in induced sputum: implications for clinical trials in cystic fibrosis","volume":"14","author":"Chmiel","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.08.007_bib0034","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2021.08.007_bib0035","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacafor for CF with a single Phe508del mutation","author":"Middleton","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321013485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321013485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:45:37Z","timestamp":1761601537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199321013485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1569199321013485"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2021.08.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2021.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}